TransCode Therapeutics, Inc. (RNAZ) Income Statement
RNAZ 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsRNAZ revenue and net income
RNAZ growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RNAZ quarterly EPS vs estimates
TransCode Therapeutics beat the analyst EPS estimate in 1 of the last 5 quarters. Next report: November 13, 2026.
RNAZ income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $114,177 | $534,857 | $516,746 | $98,606 | $42,470 | — | — | — |
| Gross profit | −$114,177 | −$534,857 | −$516,746 | −$98,606 | −$42,470 | — | — | — |
| Research & development | $13.4M | $9.6M | $12.3M | $10.2M | $2.8M | $284,459 | $226,309 | $82,532 |
| Sales, general & admin | $5.8M | $6.0M | $7.15B | $8.4M | $3.4M | $442,145 | $230,556 | $301,464 |
| Total operating expenses | $28.0M | $15.1M | $18.9M | $18.6M | $6.1M | $726,604 | $456,865 | $384,518 |
| Operating income | −$28.0M | −$15.7M | −$19.4M | −$18.7M | −$6.2M | −$726,604 | −$456,865 | −$383,996 |
| Interest income | $79,198 | $684 | $14,784 | $20,410 | $664 | $136 | $34 | — |
| Interest expense | $6,616 | $26,813 | $55,899 | $17.6M | $95,070 | $394,573 | $156,965 | $0 |
| Income before taxes | −$34.4M | −$16.8M | −$18.5M | −$17.6M | −$6.8M | −$2.3M | −$607,212 | −$453,440 |
| Income taxes | $226,068 | −$16.79B | $4 | $17.6M | $95,070 | $394,437 | $156,931 | −$69,444 |
| Net income | −$34.7M | −$16.8M | −$18.5M | −$17.6M | −$6.8M | −$2.3M | −$607,212 | −$453,440 |
| EBITDA | −$34.3M | −$16.2M | −$18.0M | −$17.5M | −$6.7M | −$1.9M | −$450,247 | −$69,444 |
| EPS (diluted) | −$1313.52 | −$29385.01 | −$184319.02 | −$798336.70 | −$170015.79 | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $753,146 | $0 | $0 |
| Cost of revenue | $23,937 | $23,936 | — | $4,781 | $13,443 | $51,174 | −$284,482 | $127,521 | $142,835 | $140,173 | — | $138,783 |
| Gross profit | −$23,937 | −$23,936 | — | −$4,781 | −$13,443 | −$51,174 | $284,482 | −$127,521 | −$142,835 | −$140,173 | — | −$138,783 |
| Research & development | $3.7M | $5.11B | $5.5M | $3.2M | $2.6M | $2.2M | $1.2M | $1.2M | $3.1M | $1.8M | $3.4M | $3.3M |
| Sales, general & admin | $2.5M | $2.22B | $1.8M | $1.4M | $1.7M | $951,652 | $938,025 | $938,025 | $2.0M | $1.5M | $695,408 | $2.0M |
| Total operating expenses | $6.8M | $7.3M | $6.5M | $4.6M | $4.2M | $3.2M | $2.2M | $2.0M | $5.1M | $3.3M | $4.0M | $5.2M |
| Operating income | −$6.8M | −$7.3M | −$6.5M | −$4.6M | −$4.2M | −$3.2M | −$2.1M | −$2.2M | −$5.1M | −$3.3M | −$4.0M | −$5.3M |
| Interest income | $52,168 | $91,888 | $78,757 | $147 | $148 | $146 | $159 | $179 | $178 | $168 | $137 | $131 |
| Interest expense | $0 | $542 | $542 | $5,960 | $0 | $114 | $10,793 | $10,792 | $4,482 | $9,706 | — | $17,282 |
| Income before taxes | −$6.7M | −$17.6M | −$13.2M | −$4.9M | −$4.3M | −$12.1M | −$2.4M | −$2.3M | −$5.2M | −$3.3M | −$4.1M | −$5.3M |
| Income taxes | −$300 | $231,309 | — | — | — | — | $179,479 | $179,479 | −$5 | −$3 | — | $27,441 |
| Net income | −$6.7M | −$17.8M | −$13.4M | −$4.9M | −$4.3M | −$12.1M | −$2.4M | −$2.3M | −$5.2M | −$3.3M | −$4.1M | −$5.3M |
| EBITDA | −$6.7M | −$17.5M | −$13.2M | −$4.8M | −$4.3M | −$12.0M | −$21,342 | −$2.2M | −$5.0M | −$3.2M | — | −$5.2M |
| EPS (diluted) | −$7.17 | −$21.28 | −$16.42 | −$5.82 | −$5.13 | −$1286.15 | −$1286.15 | −$147.84 | −$27350.42 | −$600.60 | −$627.33 | −$62092.84 |
| Gross margin | — | — | — | — | — | — | — | — | — | −18.6% | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | −436.7% | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | −441.7% | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RNAZ's financial statements (latest annual report filed April 15, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RNAZ financial results
TransCode Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $34.7 million. Diluted earnings per share came to −$1313.52.
See the RNAZ stock overview for the latest quote and news, or the RNAZ chart for price history and technical indicators.
RNAZ income statement FAQ
Does TransCode Therapeutics have revenue?
TransCode Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is TransCode Therapeutics profitable?
No. TransCode Therapeutics reported a net loss of $34.7 million in fiscal 2025.
How much does TransCode Therapeutics spend on research and development?
TransCode Therapeutics spent $13.4 million on research and development in fiscal 2025.
What are TransCode Therapeutics's earnings per share?
TransCode Therapeutics earned $-1313.52 per diluted share in fiscal 2025, compared with $-29385.01 a year earlier.
When will TransCode Therapeutics report its next earnings?
TransCode Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does TransCode Therapeutics's fiscal year end?
TransCode Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 15, 2026.